Related references
Note: Only part of the references are listed.One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
Retinol binding protein-4 levels and clinical features of type 2 diabetes patients
Kohzo Takebayashi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women - The Women's Health Initiative Observational Study
Yiqing Song et al.
DIABETES CARE (2007)
A review of the effects of anti hyperglycaemic agents on body weight: the potential of incretin targeted therapies
Anthony Barnett et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Rinnonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes
Young Min Cho et al.
DIABETES CARE (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
The fatty liver and insulin resistance
H Yki-Järvinen et al.
CURRENT MOLECULAR MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Resistin is an inflammatory marker of atherosclerosis in humans
MP Reilly et al.
CIRCULATION (2005)
Abnormal glucose homeostasis due to chronic hyperresistinemia
SM Rangwala et al.
DIABETES (2004)
The role of sulphonylureas in the management of type 2 diabetes mellitus
M Rendell
DRUGS (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Medical consequences of obesity
GA Bray
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans
M Yannakoulia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway
HX Hui et al.
ENDOCRINOLOGY (2003)
Obesity and type 2 diabetes
CA Maggio et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2003)
Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
C Tourrel et al.
DIABETES (2001)
The hormone resistin links obesity to diabetes
CM Steppan et al.
NATURE (2001)
Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
R Perfetti et al.
ENDOCRINOLOGY (2000)
Share Paper
